Section R9-6-386. Vancomycin-Resistant or Vancomycin-Interme- diate Staphylococcus aureus

Case control measures:

1.        A diagnosing health care provider or an administrator of a health care institution, either personally or through a rep- resentative, shall isolate and implement contact precau- tions for a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus.

2.        A local health agency, in consultation with the Depart- ment, shall:

a.        Upon receiving a report under R9-6-202 of a case or suspect case of vancomycin-resistant or vancomy- cin-intermediate Staphylococcus aureus, notify the Department within 24 hours after receiving the report and provide to the Department the informa- tion contained in the report;

b.        Isolate a case or suspect case of vancomycin-resis- tant or vancomycin-intermediate Staphylococcus aureus as necessary to prevent transmission;

c.        Conduct an epidemiologic investigation of each reported case or suspect case of vancomycin-resis- tant or vancomycin-intermediate Staphylococcus aureus;

d.        For each case of vancomycin-resistant or vancomy- cin-intermediate Staphylococcus aureus, submit to the Department, as specified in Article 2, Table 4, the information required under R9-6-206(D); and

e.        Ensure that an isolate from each case of vancomy- cin-resistant or vancomycin-intermediate Staphylo-

coccus  aureus  is   submitted  to  the   Arizona  State Laboratory.

Historical Note

Section renumbered from R9-6-374 and amended by final rulemaking at 10 A.A.R. 3559, effective October 2, 2004 (Supp. 04-3). Former R9-6-386 renumbered to R9-6-392; new R9-6-386 renumbered from R9-6-380 and amended by final rulemaking at 14 A.A.R. 1502, effective April 1, 2008 (Supp. 08-2).